scholarly journals Etirinotecan Pegol

2020 ◽  
Author(s):  
Keyword(s):  
Etirinotecan Pegol

scholarly journals Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors

2018 ◽  
Vol 81 (5) ◽  
pp. 897-909 ◽  
Author(s):  
Sherwin K. B. Sy ◽  
Yen Lin Chia ◽  
Toufigh Gordi ◽  
Ute Hoch ◽  
Michael A. Eldon
Keyword(s):  
Population Pharmacokinetics ◽  
Cancer Patients ◽  
Solid Tumors ◽  
Etirinotecan Pegol

Abstract C54: Combination of PARP inhibitor talazoparib with etirinotecan pegol exhibits synergistic anti-tumor effect in non-BRCA preclinical cancer models

2015 ◽  
Author(s):  
Ying Feng ◽  
Yuqiao (Jerry) Shen ◽  
Leonard E. Post ◽  
Steve Doberstein ◽  
Deborah Charych ◽  
...  
Keyword(s):  
Parp Inhibitor ◽  
Cancer Models ◽  
Etirinotecan Pegol

scholarly journals Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer

2017 ◽  
Vol 80 (6) ◽  
pp. 1161-1169 ◽  
Author(s):  
Heinz-Josef Lenz ◽  
Philip Philip ◽  
Mark Saunders ◽  
Tatjana Kolevska ◽  
Kalyan Mukherjee ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Randomized Study ◽  
Line Treatment ◽  
Second Line ◽  
Etirinotecan Pegol

Etirinotecan pegol (EP, NKTR-102) in the treatment of high-grade glioma (HGG): A phase 2 trial.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 2096-2096
Author(s):  
Seema Nagpal ◽  
Cathy Kahn Recht ◽  
Urooj Imtiaz ◽  
Sophie Bertrand ◽  
Reena Parada Thomas ◽  
...  
Keyword(s):  
High Grade Glioma ◽  
High Grade ◽  
Phase 2 ◽  
Phase 2 Trial ◽  
Etirinotecan Pegol
Sign in / Sign up

Export Citation Format

Share Document